Diabetic Gastroparesis Market Size

DelveInsight’s ‘Diabetic Gastroparesis (DGp) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DGp in the 7 Major Markets (MM) ,i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Diabetic Gastroparesis (DGp) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan



Study Period: 2017-2030


Diabetic Gastroparesis (DGp) - Disease Understanding

The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Symptoms associated with diabetic gastroparesis are early satiety, prolonged fullness, bloating, nausea and vomiting, and abdominal discomfort and pain. These symptoms are vague and nonspecific.


The DelveInsight Diabetic Gastroparesis (DGp) market report gives the thorough understanding of the Diabetic Gastroparesis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Diabetic Gastroparesis in the 7MM.


Diabetic Gastroparesis Epidemiology

The Diabetic Gastroparesis (DGp) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of Diabetic Gastroparesis, prevalence of Gastroparesis associated with types of Diabetes Mellitus, prevalence of Diabetic Gastroparesis based on gender, prevalence of symptoms associated with Diabetic Gastroparesis) scenario of Diabetic Gastroparesis (DGp) in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017-2030.


According to DelveInsight, Total prevalent population of Diabetic Gastroparesis in 7 EM was observed to be 12,843,848 cases in 2017.


Diabetic Gastroparesis Drug Chapters

This segment of the Diabetic Gastroparesis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs along with other potential therapeutic candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


The treatment landscape of DGp comprises of very few pharmacotherapies. The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents and antiemetic agents. The first line of management is focused on optimization of glycemic control known as dietary therapy in addition with the prokinetic therapy in order to improve gastric emptying and gastroparesis symptoms.


Diabetic Gastroparesis Market Outlook

The Diabetic Gastroparesis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the market of Diabetic Gastroparesis in 7MM was found to be USD 1339.70 Million in 2017, and is expected to increase during the course of the study period (2017-2030). US accounts for the largest market size of Sickle Cell Disease, in comparison to the other 7 Major Markets i.e., United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Diabetic Gastroparesis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Diabetic Gastroparesis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Diabetic Gastroparesis Report Key Strengths

• 11 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Market Size by Therapies

• Drugs Uptake


Diabetic Gastroparesis Report Assessment


• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Diabetic Gastroparesis market

• Organize sales and marketing efforts by identifying the best opportunities for Diabetic Gastroparesis market

• To understand the future market competition in the Diabetic Gastroparesis market.


What is Diabetic Gastroparesis?

Diabetic Gastroparesis is a serious complication of diabetes that results in delayed gastric emptying with associated upper gastrointestinal symptoms in the absence of any mechanical obstruction.


What is forecasted Diabetic Gastroparesis market size in 2030

Market Size of Diabetic Gastroparesis in the 7MM is expected to reach USD 4331.47 million by 2030.


What are the Diabetic Gastroparesis market drivers?

Untapped market, Increased awareness, Novel therapeutic options, and Advances in Continuous Glucose Monitoring (CGM) techniques are the Diabetic Gastroparesis market drivers


What are the Diabetic Gastroparesis market barriers?

Impaired quality of life, Crude epidemiological data, Treatment associated barriers, and Disease associated burden are the Diabetic Gastroparesis market barriers


How many companies are developing drugs for Diabetic Gastroparesis?

Allergan, Evoke Pharma , Theravance Biopharma, Censa Pharmaceuticals, CinDome Pharma are developing drugs for Diabetic Gastroparesis

1. Key Insights

2. Executive Summary

3. SWOT Analysis for Diabetic Gastroparesis (DGp)

4. Diabetic Gastroparesis Market Overview at a Glance

4.1. Market Share (%) Distribution of Diabetic Gastroparesis in 2017

4.2. Market Share (%) Distribution of Diabetic Gastroparesis in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology and risk factors

5.3. Signs and Symptoms

5.4. Pathogenesis of Diabetic Gastroparesis

5.5. Diagnosis

5.5.1. Clinical Scoring System

5.5.2. Differential diagnosis of Diabetic Gastroparesis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Diabetic Gastroparesis

7. Country Wise-Epidemiology of Diabetic Gastroparesis

7.1. The United States

7.1.1. Assumptions and Rationale

7.1.2. Total Prevalent Cases of Diabetic Gastroparesis in the United States

7.1.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the United States

7.1.4. Prevalence of Diabetic Gastroparesis based on Gender in the United States

7.1.5. Prevalence of Symptoms associated with DGp in the United States

7.2. EU5

7.2.1. Assumptions and Rationale

7.3. Germany

7.3.1. Total Prevalent Cases of Diabetic Gastroparesis in Germany

7.3.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany

7.3.3. Prevalence of Diabetic Gastroparesis based on Gender in Germany

7.3.4. Prevalence of Symptoms associated with DGp in Germany

7.4. France

7.4.1. Total Prevalent Cases of Diabetic Gastroparesis in France

7.4.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France

7.4.3. Prevalence of Diabetic Gastroparesis based on Gender in France

7.4.4. Prevalence of Symptoms associated with DGp in France

7.5. Italy

7.5.1. Total Prevalent Cases of Diabetic Gastroparesis in Italy

7.5.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy

7.5.3. Prevalence of Diabetic Gastroparesis based on Gender in Italy

7.5.4. Prevalence of Symptoms associated with DGp in Italy

7.6. Spain

7.6.1. Total Prevalent Cases of Diabetic Gastroparesis in Spain

7.6.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain

7.6.3. Prevalence of Diabetic Gastroparesis based on Gender in Spain

7.6.4. Prevalence of Symptoms associated with DGp in Spain

7.7. The United Kingdom

7.7.1. Total Prevalent Cases of Diabetic Gastroparesis in the UK

7.7.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK

7.7.3. Prevalence of Diabetic Gastroparesis based on Gender in the UK

7.7.4. Prevalence of Symptoms associated with DGp in the UK

7.8. Japan

7.8.1. Assumptions and Rationale

7.8.2. Total Prevalent Cases of Diabetic Gastroparesis in Japan

7.8.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan

7.8.4. Prevalence of Diabetic Gastroparesis based on Gender in Japan

7.8.5. Prevalence of Symptoms associated with DGp in Japan

8. Treatment and Management of Diabetic Gastroparesis

8.1. Consensus guidelines for the clinical management of diabetic gastroparesis

8.2. Algorithm for the management of diabetic gastroparesis

8.3. Patient Journey for Diabetic Gastroparesis

9. Case study for Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Drugs

11.1. Metoclopramide: ANI Pharmaceuticals, Inc

11.1.1. Drug Description

11.1.2. Regulatory Milestones

11.1.3. Other Development Activities

11.1.4. Safety and Efficacy

12. Emerging Therapies

12.1. Relamorelin: Allergan

12.1.1. Product Description

12.1.2. Other Development Activities

12.1.3. Clinical Development

12.1.4. Safety and Efficacy

12.2. Metoclopramide Nasal Spray (Gimoti): Evoke Pharma Inc.

12.2.1. Product Description

12.2.2. Other Development Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.3. Velusetrag: Theravance Biopharma

12.3.1. Product Description

12.3.2. Other Development Activities

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.4. Sepiapterin (CNSA-001): Censa Pharmaceuticals

12.4.1. Product Description

12.4.2. Clinical Development

12.5. CIN-102: CinDome Pharma

12.5.1. Product Description

12.5.2. Clinical Development

12.5.3. Safety and Efficacy

13. Other products of interest

13.1. TAK-954: Takeda (Millennium Pharmaceuticals, Inc.)

13.1.1. Product Description

13.1.2. Other Development Activities

13.1.3. Clinical Development

13.2. TAK-906: Takeda (Millennium Pharmaceuticals, Inc.)

13.2.1. Product Description

13.2.2. Other Development Activities

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.3. Nimacimab: Bird Rock Bio

13.3.1. Product Description

13.3.2. Other Development Activities

13.3.3. Clinical Development

14. Diabetic Gastroparesis: 7 Major Market Analysis

14.1. Key Findings

14.2. Market Size of Diabetic Gastroparesis in 7MM

14.2.1. Market Size of Diabetic Gastroparesis by Therapies

15. Market Outlook by Country

15.1. United States: Market Outlook

15.2. The United States Market Size

15.2.1. Total Market Size of Diabetic Gastroparesis

15.2.2. Market Size of Diabetic Gastroparesis by Therapies

16. EU-5 Countries: Market Outlook

16.1. Germany

16.1.1. Total Market size of Diabetic Gastroparesis

16.1.2. Market Size of Diabetic Gastroparesis by Therapies

16.2. France

16.2.1. Total Market Size of Diabetic Gastroparesis

16.2.2. Market Size of Diabetic Gastroparesis by Therapies

16.3. Italy

16.3.1. Total Market Size of Diabetic Gastroparesis

16.3.2. Market Size of Diabetic Gastroparesis by Therapies

16.4. Spain

16.4.1. Total Market Size of Diabetic Gastroparesis

16.4.2. Market Size of Diabetic Gastroparesis by Therapies

16.5. The United Kingdom

16.5.1. Total Market Size of Diabetic Gastroparesis

16.5.2. Market Size of Diabetic Gastroparesis by Therapies

17. Japan: Market Outlook

17.1. Total Market Size of Diabetic Gastroparesis

17.2. Market Size of Diabetic Gastroparesis by Therapies

18. Market Access and Reimbursement Overview of DGp

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Bibliography

21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Table 1: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)

Table 2: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)

Table 3: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)

Table 4: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)

Table 5: Prevalence of Symptoms associated with DGp in the United States (2017-2030)

Table 6: Total Prevalent Cases of Diabetic Gastroparesis in Germany (2017-2030)

Table 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)

Table 8: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)

Table 9: Prevalence of Symptoms associated with DGp in the Germany (2017-2030)

Table 10: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)

Table 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)

Table 12: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)

Table 13: Prevalence of Symptoms associated with DGp in France (2017-2030)

Table 14: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)

Table 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)

Table 16: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)

Table 17: Prevalence of Symptoms associated with DGp in Italy (2017-2030)

Table 18: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)

Table 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)

Table 20: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)

Table 21: Prevalence of Symptoms associated with DGp in Spain (2017-2030)

Table 22: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)

Table 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)

Table 24: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)

Table 25: Prevalence of Symptoms associated with DGp in the UK (2017-2030)

Table 26: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)

Table 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)

Table 28: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)

Table 29: Prevalence of Symptoms associated with DGp in Japan (2017-2030)

Table 30: Relamorelin Clinical Trial Description, 2020

Table 31: Metoclopramide Nasal Spray ( Gimoti)Clinical Trial Description, 2020

Table 32: Velusetrag, Clinical Trial Description, 2020

Table 33: CNSA-001, Clinical Trial Description, 2020

Table 34: Velusetrag, Clinical Trial Description, 2020

Table 35: TAK-954, Clinical Trial Description, 2020

Table 36: TAK-906, Clinical Trial Description, 2020

Table 37: Nimacimab, Clinical Trial Description, 2020

Table 38: 7 Major Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 39: 7 Major Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 40: United States Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 41: The US Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 42: Germany Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 43: Germany Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 44: France Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 45: France Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 46: Italy Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 47: Italy Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 48: Spain Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 49: Spain Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 50: United Kingdom Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 51: The UK Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Table 52: Japan Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Table 53: Japan Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 1: SWOT Analysis

Figure 2: Glucose and gastric emptying: bidirectional relationship

Figure 3: Pathophysiology of diabetic gastroparesis

Figure 4: Diagnosis algorithm for Diabetic Gastroparesis

Figure 5: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)

Figure 6: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)

Figure 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)

Figure 8: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)

Figure 9: Prevalence of Symptoms associated with DGp in the United States (2017-2030)

Figure 10: Total Prevalent Cases of Diabetic Gastroparesis in the Germany (2017-2030)

Figure 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)

Figure 12: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)

Figure 13: Prevalence of Symptoms associated with DGp in Germany (2017-2030)

Figure 14: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)

Figure 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)

Figure 16: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)

Figure 17: Prevalence of Symptoms associated with DGp in France (2017-2030)

Figure 18: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)

Figure 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)

Figure 20: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)

Figure 21: Prevalence of Symptoms associated with DGp in Italy (2017-2030)

Figure 22: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)

Figure 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)

Figure 24: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)

Figure 25: Prevalence of Symptoms associated with DGp in Spain (2017-2030)

Figure 26: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)

Figure 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)

Figure 28: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)

Figure 29: Prevalence of Symptoms associated with DGp in the UK (2017-2030)

Figure 30: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)

Figure 31: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)

Figure 32: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)

Figure 33: Prevalence of Symptoms associated with DGp in Japan (2017-2030)

Figure 34: Suggested therapeutic options for gastroparesis

Figure 35: Algorithm for the management of diabetic gastroparesis.

Figure 36: Patient Journey for DG

Figure 37: Unmet Needs of Diabetic Gastroparesis

Figure 38: 7 Major Market Size of Diabetic Gastroparesis in USD Million (2017-2030)

Figure 39: 7 Major Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 40: Market Size of Diabetic Gastroparesis in France, USD Million (2017-2030)

Figure 41: The US Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 42: Market Size of Diabetic Gastroparesis in Germany, USD Million (2017-2030)

Figure 43: Germany Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 44: Market Size of Diabetic Gastroparesis in France USD Million (2017-2030)

Figure 45: France Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 46: Market Size of Diabetic Gastroparesis in Italy, USD Million (2017-2030)

Figure 47: Italy Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 48: Market Size of Diabetic Gastroparesis in Spain, USD Million (2017-2030)

Figure 49: Spain Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 50: Market Size of Diabetic Gastroparesis in the United Kingdom, USD Million (2017-2030)

Figure 51: The UK Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 52: Market Size of Diabetic Gastroparesis in Japan, USD Million (2017-2030)

Figure 53: Japan Market Size of Diabetic Gastroparesis by Therapies in USD Million (2017-2030)

Figure 54: Market Drivers

Figure 55: Market Barriers

  • Tags:
  • Diabetic Gastroparesis (DGp) - Mark...
  • Epidemiology and Market Forecast-2...

Forward to Friend

Need A Quote